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Abstract: Fibromyalgia (FM) is a chronic syndrome characterized by widespread musculoskeletal
pain, and physical and emotional symptoms. Although its pathophysiology is largely unknown,
immune-inflammatory pathways may be involved. We examined serum interleukin (IL)-6,
high sensitivity C-reactive protein (hs-CRP), CXCL-8, and IL-10 in 67 female FM patients and
35 healthy women while adjusting for age, body mass index (BMI), and comorbid disorders.
We scored the Fibromyalgia Severity Score, Widespread Pain Index (WPI), Symptom Severity Scale
(SSS), Hospital Anxiety (HADS-A), and Depression Scale and the Perceived Stress Scale (PSS-10).
Clinical rating scales were significantly higher in FM patients than in controls. After adjusting for
covariates, IL-6, IL-10, and CXCL-8 were lower in FM than in HC, whereas hs-CRP did not show any
difference. Binary regression analyses showed that the diagnosis FM was associated with lowered
IL-10, quality of sleep, aerobic activities, and increased HADS-A and comorbidities. Neural networks
showed that WPI was best predicted by quality of sleep, PSS-10, HADS-A, and the cytokines, while
SSS was best predicted by PSS-10, HADS-A, and IL-10. Lowered levels of cytokines are associated
with FM independently from confounders. Lowered IL-6 and IL-10 signaling may play a role in the
pathophysiology of FM.
Keywords: fibromyalgia; widespread pain; cytokines; inflammation; neuro-immune
1. Introduction
Fibromyalgia (FM) is a chronic syndrome of unknown pathophysiology characterized by
widespread musculoskeletal pain coupled with fatigue, stiffness, disordered sleep, perceived cognitive
dysfunction, and mood disturbances [1]. One of the current hypotheses suggests that an unbalanced
immune system may play a role in the pathophysiology of FM [2]. Several studies evaluated the
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role of interleukins (IL), chemokines, and immune-related substances in FM, resulting in inconsistent
results. For example, increased levels of IL-6, CXCL-8, high-sensitivity C-reactive protein (hs-CRP),
and IL-10 were found in some [3–5], but not all studies [6–8]. Moreover, other results supported the
view that FM may be accompanied by suppression of the immune-inflammatory response system
(IRS) [8]. In addition, in order to obtain a more comprehensive picture of immune function in FM, it is
important to consider not only biomarkers of the IRS, including CXCL-8 and hs-CRP, but also immune
regulatory or anti-inflammatory cytokines, including IL-10, and cytokines with combined IRS and
regulatory properties such as IL-6 [9].
Results of published systematic reviews and meta-analyses indicate that methodological
differences among immune studies are a main source of inconsistent results [10,11]. Major sources of
heterogeneity might be due to uncontrolled variables including age, sex, body mass index (BMI) [12],
sleep disorders [13,14], or comorbid medical disorders [15,16]. In addition, there is a wide range
of clinical extraneous variables that were constantly disregarded, including depressive and anxiety
symptoms [17,18], intake of antidepressants (ADs) [19,20], menopause [21], use of anticonvective
hormones [22], aerobic exercise [23,24], seasonality, and diurnal variations [25,26].
Hence, in this case-control study we examine serum levels of pro-inflammatory markers, including
CXCL-8 and hs-CRP, as well as IL-6 and the major negative immune-regulatory cytokine IL-10 in FM as
compared with healthy controls, while adjusting for most of the above-mentioned extraneous variables.
Based on the immune-inflammatory hypothesis of FM, the specific hypothesis is that - after controlling
for relevant socio-demographic and biomedical confounders - FM is characterized by higher levels of
IL-6, CXCL-8, and hs-CRP and lowered or unchanged levels of IL-10. Additionally, the predicting
ability of the inflammatory biomarkers along with other predictors (e.g., severity of depression and
anxiety) was examined using neuronal network (NN) machine learning. NN is well suited to discover
more complex nonlinear relationships between input variables (i.e., cytokines, depression, anxiety)
predicting FM diagnosis and widespread pain scores (the outcome variables) while examining multiple
interrelated factors. Additionally, NN allows to rank the input variables in order of predictive power
of the features.
2. Results
2.1. Socio-Demographic and Clinical Data in Patients and Controls
No significant differences were found between cases and controls in age, living arrangement,
menopause, perceived healthy diet, or smoking. Patients showed significant lower education,
employment status, and more use of medication, number of comorbidities, and a higher BMI,
as compared with controls. The WPI, SSS, and FS scores were significantly higher in FM than in
controls. The severity of FM as assessed with FIQ-R in FM patients was moderate [27], and they
suffered from FM for 13.0 (±9.5) years. All clinical rating scale scores were significantly different
between the two groups. Table 1 shows the raw data of the 4 biomarkers in both study groups,
while Electronic Figures S1 and S2 illustrate the biomarker differences between the study groups.
Nevertheless, we would refer the reader to Tables 2 and 3 which computes the estimated marginal
means of the immune biomarker data after adjustment for the relevant confounders.
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Table 1. Socio-demographic, clinical and biomarker data in patients with fibromyalgia (FM) and
healthy controls (HC).
Variables FM (n = 66) HC (n = 35) p
Sociodemographic & biometric variables
Age (years) 53.36 (8.05) 54.43 (7.84) 0.55
Employed (n, %) 26 (38.40) 26 (74.30%) <0.001 *
With primary studies or more (n, %) 62 (94.00%) 35 (100.00%) <0.001 *
Living with someone (n, % Yes) 61 (90.10%) 30 (85.70%) 0.23
BMI (kg/m2) 28.79 (5.27) 24.03 (3.67) <0.001 *
Duration of illness (years) 12.98 (9.48) na na
In menopause (n, % Yes) 33 (55.00%) 22 (62.90%) 0.72
Number of comorbidities 0.97 (1.24) 0.26 (0.51) <0.001 *
Antidepressants intake (n, % Yes) 25 (37.90%) 1 (2.90%) <0.001 *
Clinical variables
FIQ-R (0–100) 59.51 (21.06)
WPI (0–19) 13.5 (3.70) 1.6 (1.80) <0.001 *
SSS (0–12) 8.4 (2.60) 2.1 (1.80) <0.001 *
FS (0–31) 22.00 (5.50) 3.6 (3.20) <0.001 *
HADS_A (0–21) 10.55 (4.41) 6.17 (3.20) <0.001 *
HADS_D (0–21) 7.77 (5.06) 3.14 (3.33) <0.001 *
HADS Total (0–42) 18.32 (8.17) 9.20 (6.07) <0.001 *
PSS-10 (0–40) 22.00 (9.47) 12.57 (6.49) <0.001 *
Health behaviours
Sleep quality (0–10) 3.79 (2.07) 6.43 (1.61) <0.001 *
Healthy diet (0–10) 6.84 (2.01) 6.52 (2.25) 0.24
Smoke (n, % Yes) 12.00 (19.70%) 5.00 (14.30%) 0.36
Practice of aerobic exercise (n, % Yes) 37.00 (60.70%) 32.00 (91.40%) 0.001 *
Immune biomarkers
IL-6 (pg/mL)* 5.93 (9.27) 7.56 (5.04) 0.007 *
IL-10 (pg/mL)* 10.29 (10.78) 17.94 (15.02) 0.04 *
CXCL8 (pg/mL)* 11.68 (8.90) 14.39 (10.29) 0.04 *
hs-CRP (mg/L)* 2.69 (2.96) 1.33 (1.76) 0.005 *
Values are shown as means ±SD or n and percentages (%) where appropriate. All results of analyses of variance or
analyses of contingency tables. *Immune biomarkers were processed in Ln transformation. BMI: body mass index,
FIQ-R: Revised Fibromyalgia Impact Questionnaire; FS: Fibromyalgia Symptoms scale; HADS: Hospital Anxiety
and Depression Scale; PSS-10: Perceived Stress Scale; IL: interleukin; hs-CRP: high sensitivity C-reactive protein;
SSS: Symptom Severity Scale from the FS; WPI: Widespread Pain Index from the FS. na: no applicable.
2.2. Associations Between Cytokines and Diagnosis
Table 2 shows the results of multivariate multivariate general linear model (GLM) analyses with
the cytokines and the composite score as dependent variables and significant confounders, namely age,
BMI groups, and quality of sleep as explanatory variables. The other extraneous variables were not
significant in this analysis, including comorbidities, intake of antidepressants and other medications,
aerobic activity, sleep measurements, and clinical rating scale scores. Before adjusting for the significant
covariates, we found that there was a significant between-group difference in immune markers and
the composite score. Tests for between-subjects effects showed significant effects of diagnosis (see
also Table 1). Nevertheless, after covarying for age, quality of sleep, and BMI groups in the same
multivariate GLM analysis, we found that the effects of diagnosis on these 5 dependent variables were
no longer significant. Tests for between subjects (see Table 2) showed that there were still significant
differences between cases and controls in IL-6, CXCL-8 and IL-10 and their composite score, whereas
the effects on hs-CRP were no longer significant. P-correction for FDR shows that IL-6 (p = 0.04),
CXCL-8 (p = 0.05), IL-10 (p = 0.02) and their composite score (p = 0.02) remained significant. There
was a significant effect of BMI-groups on hs-CRP whereby the latter increased from the BMI group
Int. J. Mol. Sci. 2019, 20, 4231 4 of 16
with <25 kg/m2 (mean ±SD: −0.47 ± 0.18 in z scores) to 25–30 kg/m2 (0.23 ± 0.17) to the group with
>30 kg/m2 (0.35 ±0.20). There was a significant inverse association between IL-6 and age, while quality
of sleep showed a very modest inverse association with IL-10.
Table 2. Results of multivariate GLM analysis with the biomarkers as the dependent variables and
diagnosis as explanatory variable while adjusting for extraneous variables.
Tests Dependent Variables Explanatory Variables F df p
Multivariate 4 cytokines + 1 composite Diagnosis 3.50 4/96 0.010 *
Between-subject
effects
IL-6 Diagnosis 7.54 1/99 0.007 *
CXCL-8 Diagnosis 4.59 1/99 0.035 *
IL-10 Diagnosis 5.00 1/99 0.028 *
hs-CRP Diagnosis 8.44 1/99 0.005 *
zIL6 + zIL10 + zCXCL-8 Diagnosis 8.74 1/99 0.004 *
Multivariate 4 cytokines + 1 composite
Diagnosis 2.20 4/92 0.075
Age 2.81 4/92 0.030 *
QoSleep 1.81 4/92 0.134
BMI groups 1.81 8/186 0.077
Between-subject
effects
IL-6 Diagnosis 5.45 1/95 0.022 *
CXCL-8 Diagnosis 4.40 1/95 0.039 *
IL-10 Diagnosis 7.11 1/95 0.009 *
hs-CRP Diagnosis 0.70 1/95 0.406
zIL6 + zIL10 + zCXCL-8 Diagnosis 8.78 1/95 0.004 *
hs-CRP BMI groups 6.46 1/95 0.002 *
IL-10 QoSleep 4.40 1/95 0.039 *
IL-6 Age 8.51 1/95 0.004 *
Diagnosis: Fibromyalgia versus healthy controls. IL: interleukin; hs-CRP: high sensitivity C-reactive protein. zIL6 +
zIL10 + zCXCL-8: composite score computed as the sum of z values of these biomarkers; QoSleep: Quality of Sleep.
BMI groups: <25 kg/m2, 25–30 kg/m2, >30 kg/m2. Note:Immune biomarkers were processed in Ln transformation.
Table 3. Model-generated estimated marginal means of the immune biomarkers obtained by GLM
analysis shown in Table 2 in healthy controls (HC) and patients with fibromyalgia syndrome (FMS).
Variables HC FMS
zIL-6 0.370 (0.196) −0.218 (0.124)
zCXCL-8 0.338 (0.205) −0.215 (0.130)
zIL-10 0.446 (0.204) −0.253 (0.129)
zhs-CRP −0.069 (0.190) 0.135 (0.120)
zIL6 + zIL10 + zCXCL-8 0.472 (0.198) −0.281 (0.125)
Note: IL: interleukin; hs-CRP: high sensitivity C-reactive protein. zIL6 + zIL10 + zCXCL-8: composite score
computed as the sum of the z values of these biomarkers. Comparing FM patients who did not take any medication
and HC, the between-group differences disappeared and only CXCL-8 was found lower in FM.
Table 3 shows the mean values of the five immune markers in z scores after adjusting for
the confounders. IL-6, CXCL-8, IL-10, and the composite score were significantly lower in FM as
compared with controls, while there were no differences in hs-CRP. For example, the difference in
IL-10 between both study groups showed that IL-10 was 0.70 SDs lower in FM than in HC. There
were no significant effects of the use of ADs on the five immune biomarkers, either in a multivariate
GLM analysis (F = 1.07, df = 4/91, p = 0.38) or tests for between-subject effects (all p > 0.22 even
without p-correction for FDR). There was no significant effect of the use of pain killers on the same
biomarkers. There were no significant differences in the five biomarkers between a) subjects with and
without a current episode of major depression either using multivariate GLM (F = 0.15, df = 4/57,
p = 0.96) or tests for between-subjects effects (all p > 0.52), and b) subjects with and without a lifetime
episode of major depression either using multivariate GLM (F = 1.35, df = 4/57, p = 0.27) or tests for
between-subjects effects (all p > 0.08). There were no significant effects of smoking (yes/no) on the five
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immune biomarkers, either in a multivariate GLM analysis (F = 0.77, df = 4/87, p = 0.55) or tests for
between-subject effects (all p > 0.20 even without p-correction for FDR).
2.3. Prediction of FM
In order to check the best predictors of FM as dependent variable (with controls as reference
group) we performed logistic regression analyses. We entered the cytokines as explanatory variables
while possible confounders were comorbidities, quality of sleep, aerobic exercise, HADS-A, HADS-D,
and PSS-10. Adding smoking as a covariate (forced entry) showed that there was no significant effect
of smoking on the outcome of these regression analyses. The first logistic regression analysis shown in
Table 4 indicates that FM was best predicted by IL-10 even after controlling for quality of sleep, aerobic
exercise (all inversely) and comorbidities (positively) (χ2 = 63.32, df = 4, p < 0.001, Nagelkerke = 0.64).
We performed a second regression analysis without comorbidities as explanatory variable and found
that FM was predicted by IL-10 even after adjusting for quality of sleep (both inversely) and HADS-A
(χ2 = 52.38, df = 3, p < 0.001, Nagelkerke = 0.56). These findings show that IL-10 is a better predictor of
FM than IL-6 and CXCL-8 and that the inverse association between IL-10 and FM remains significant
after adjusting for quality of sleep, HADS-A, and aerobic exercise.
Table 4. Results of binary logistic regression analysis with FM group membership as dependent variable
(with healthy controls as reference group) and the immune biomarkers as explanatory variables.
No ExplanatoryVariables B SE Wald df p OR 95% CI
#1
IL-10 −0.710 0.337 4.447 1 0.035 0.492 0.254–0.951
Comorbidities 1.302 0.653 3.976 1 0.046 3.676 1.022–13.218
QoSleep −1.020 0.236 18.720 1 <0.001 0.360 0.227–0.572
Aerobic exercise −2.738 0.956 8.201 1 0.004 0.065 0.010–0.421
#2
IL-10 −0.742 0.325 5.211 1 0.022 0.476 0.252–0.900
HADS-A 0.179 0.080 5.014 1 0.025 1.196 1.023–1.399
QoSleep −0.816 0.203 16.157 1 <0.001 0.442 0.297–0.658
OR: Odds ratio, CI: confidence intervals. All variables were entered as z scores. IL: Interleukin; QoSleep: Quality of
sleep; HADS-A: Anxiety sub-scale of the Hospital Anxiety and Depression Scale.
2.4. Results of NN
NN was employed to predict the FS rating subscales scores (WPI and SSS scores) as well as the
FM diagnosis using 11 predictors as input variables, namely the 4 immune biomarkers, HADS-D,
HADS-A, PSS-10, BMI-groups (split according to a BMI of 25.0 kg/m2), comorbidities, quality of sleep,
and aerobic activity. The summaries of the automatic architecture training of the network models are
shown in Table 5.
NN model #1 (with WPI as output variable) was trained with two hidden layers with 4 units in
hidden layer 1 and 3 units in hidden layer 2. Both layers employed hyperbolic tangent as activation
function, while the output layer used identity as activation function. This neural network used the sum
of squares as error term. Table 5, NN model #1 shows the model summary data. During the training,
model #1 minimized the error term, indicating that the model learnt to generalize from the trend.
The relative error terms were fairly constant among the training and either testing or holdout sample
indicating that the trained models were not overtrained. The correlation coefficient between the WPI
score and the model-predicted value was r = 0.60. Figure 1 shows the relevance chart with importance
and normalized importance of the 11 input variables. Quality of sleep, PSS-10, and HADS-A were
the most important determinants of the predictive power of the network followed by IL-6, CXCL-8,
and IL-10.
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Table 5. Multilayer Perceptron (MLP) Neural Network (NN) models with the Fibromyalgia Symptoms
Scale (FS) sub-scores or the diagnosis Fibromyalgia as output variables.
Models NN#1 NN#2 NN#3
Input Layer Number of units 11 + bias 9 11 + bias
Rescaling method Standardized Standardized Adjustednormalized
Hidden layers
Number of hidden
layers 2 1 2
Number of units in
hidden layer 1 4 4 3
Number of units in
hidden layer 2 3 - 2
Activation Function Hyperbolic tangent Hyperbolic tangent Hyperbolic tangent
Output layer
Dependent variables WPI score SSS score
FM vs. controls
(group
membership)
Number of units 1 1 2
Rescaling method Standardized Standardized
Activation function Identity Identity Identity
Error function Sum of squares (SS) Sum of squares (SS) SS
Training
SS error 10.742 10.096 6.971
Relative error or %
incorrect 0.413 0.439 18.7%
Prediction (sensitivity -
specificity) 82.1%–80.0%
SS error 4.959 3.857 1.612
Testing
Relative error or %
incorrect 0.421 0.378 9.1%
Prediction (sensitivity -
specificity) 93.3%–83.3%
AUC ROC 0.908
Holdout
Relative error or %
incorrect 0.512 0.485 12.9%
Prediction
(sensitivity-specificity) 86.4%–88.9%
Correlation with
predicted values R = 0.598 R = 0.625
Note: SSS: Symptom Symptoms Scale from the FS; WPI: Widespread Pain Index from the FS.
Figure 1. Neural network model #1 with WPI as output. QoSleep: Quality of Sleep, PSS(-10):
Perceived Stress Scale, HADS-A: Anxiety sub-scale of the Hospital Anxiety and Depression Scale, IL:
interleukin, Comorbidities: number of total comorbid illnesses, Aerobic: aerobic exercise, times per
week, hs-CRP: high sensitivity C-reactive protein, HADS-D: Depression sub-scale of the Hospital
Anxiety and Depression Scale, BMI_25: Body Mass Index >25 kg/m2.
In NN model #2 the SSS score was the output variable while the same 11 input variable without
HADS-D and quality of sleep (because those symptoms are part of the SSS score) were introduced.
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This model was trained with one hidden layer with 4 units employing hyperbolic tangent as activation
function, while the output layer used identity as activation function. This model minimized the error
term, indicating that the model learned to generalize from the trend. The relative error terms were
fairly constant among the three samples and the correlation coefficient between the SSS score and
the model-predicted value was r = 0.63. Figure 2 shows the relevance chart with importance and
normalized importance of the 9 input variables. PSS-10, HADS-A, and IL-10 were the most important
determinants of the predictive power of NN model #2, followed at a distance by comorbidities and IL-6.
Figure 2. Neural network model #2 with SSS as output. PSS(-10): Perceived Stress Scale, HADS-A:
Anxiety sub-scale of the Hospital Anxiety and Depression Scale, IL: interleukin, Comorbidities: number
of total comorbid illnesses, BMI-groups: Body Mass Index categorical variable, Aerobic: aerobic
exercise, times per week, hs-CRP: high sensitivity C-reactive protein.
In NN model #3 the output variables were FM diagnosis and the control group with again the
same 11 input variables. Table 5, model #3 shows that the percentage of incorrectly classified cases was
relatively constant among the training, the testing or holdout samples. Figure 3 shows that the area
under the receiving operating curve (ROC) was 0.91. In the holdout set, we found that 87.1% of all
cases were correctly classified by the model. Figure 4 shows the relevance chart for the discrimination
of FM patients versus HC. Quality of sleep, HADS-A, aerobic activity, and PSS-10 were the most
important determinants of the predictive power of neural network 3, followed at a distance by BMI
groups, CXCL-8, IL-10, and comorbidities.
Figure 3. Area under the receiving operating curve (0.91) of the Neural Networking model #3 with FM
diagnose as output.
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Figure 4. Neural network model #3 with FM diagnose as output. QoSleep: Quality of Sleep, HADS-A:
Anxiety sub-scale of the Hospital Anxiety and Depression Scale, Aerobic: aerobic exercise, times per
week, PSS-10: Perceived Stress Scale, BMI: Body Mass Index, IL: interleukin, Comorbidities: number of
total comorbid illnesses, HADS-D: Depression sub-scale of the Hospital Anxiety and Depression Scale,
hs-CRP: high sensitivity C-reactive protein.
3. Discussion
The major finding of this case-control study is that, contrary to our a priori hypothesis, IL-6 and
CXCL-8 levels were significantly decreased in patients with FM compared with controls. Moreover,
IL-10 was also significantly lower in FM patients, while there were no significant differences in hs-CRP
after controlling for confounding variables. Our results on IL-6 levels are not in agreement with most
published papers, which reported higher levels of IL-6 in FM [6,28–30], although some studies found no
significant differences between FM patients and controls [4,8,31–34]. Previously, some authors reported
lower levels of CXCL-8 in FM [28,30]. Nevertheless, as with IL-6, there is a large heterogeneity between
published studies with a number of studies reporting no significant differences in CXCL-8 [3,33,35]
and some even increased CXCL-8 levels [30]. In accordance with a previous study, we found lowered
levels of IL-10 in FM [6], although other studies reported higher levels of IL-10 [3,4]. Similarly, previous
results on hs-CRP in FM were mixed with some studies reporting higher levels [34,36], while other
studies could not find any differences between FM patients and controls [37,38].
All in all, the results show that there is a large heterogeneity among studies in cytokine-chemokine
results. This is further corroborated by the results of a recent systematic review [10], which was unable
to delineate a specific immune profile in FM and concluded that the methodological quality of immune
studies in FM should be improved. A major source of heterogeneity is that most studies did not control
or only partially controlled for the potential important confounders, which may modulate immune
biomarkers. In the present study, we found that after controlling for BMI, comorbid illnesses, aerobic
exercise, anxiety, depression, perceived stress symptoms, and quality of sleep, the differences in IL-6,
IL-10, and CXCL-8 between groups remained significant, whereas hs-CRP was no longer significantly
increased in FM. Since patients with FM usually present with higher BMI values than observed in the
general population [39,40], it is plausible that the differences in hs-CRP levels reported in some studies
are attributable to effects of BMI. Previously, it was shown that BMI is also a major determinant of
increased hs-CRP values in bipolar disorder and major depression [41,42]. In this work, we have found
that two other confounders, namely age and quality of sleep, may interfere with cytokine-chemokine
measurements in FM. Firstly, age was significantly and negatively correlated with IL-6 levels, although
some but not all studies showed that IL-6 may increase with age [43]. Secondly, we found a very
modest inverse association between quality of sleep and IL-10 levels. Moreover, FM is a syndrome
with a high prevalence of comorbidities with medical and psychiatric conditions (e.g., obesity, arthrosis,
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depression, anxiety), which can influence peripheral levels of immune-inflammatory biomarkers and
which should, therefore, be considered when interpreting cytokine results. As such, the effects of
comorbidities combined with other variables including quality of sleep, BMI, age, sex, and exercise
could explain the discrepant results reported in the literature.
Another important issue is that it is difficult to interpret results on cytokines-chemokines
without considering their pro- versus anti-inflammatory profile, because the balance between
pro-/anti-inflammatory biomarkers determines the functional state of the immune system [44].
As such, we have assayed 2 pro-inflammatory mediators (CXCL-8 and hs-CRP), the major negative
immune-regulatory cytokine (IL-10) and a cytokine (IL-6) that may exhibit pro-inflammatory as well
as anti-inflammatory effects [44,45]. In this regard, z unit weighted composite scores may be computed
which denote different functional immune ratios including pro/anti-inflammatory or IRS/regulatory [44].
In our study, we expected to find immune activation as characterized by an immune profile with
increased levels of the four biomarkers or an inflammatory response as indicated by increased levels
of hs-CRP, IL-6 and CXCL-8, and possibly a relative decrease in IL-10, an anti-inflammatory and
regulatory cytokine [44]. Nevertheless, the immune profile observed in our study showed a reduction
in IL-6, IL-10, and CXCL-8 indicating that there is no clear immune activation and no inflammatory
response (according to these classic biomarkers) in our FM patients. This is important as our findings
do not corroborate the major hypothesis that IL-6 and other cytokines, which may induce pain, mental,
and cognitive impairments, are increased in that illness. Recently, IL-6 has emerged as a key regulator of
pathologic pain and administration of IL-6 may cause allodynia and hyperalgesia [46]. Pain models are
frequently accompanied by increased levels of IL-6 and the IL-6 receptor (IL-6R) in the spinal cord and
dorsal root ganglia [46]. This hyperalgesic effect of IL-6 is probably mediated via IL-6 trans-signaling
through increased levels of the soluble IL-6 receptor (sIL-6R), which binds with IL-6 to form an active
pro-inflammatory complex [47].
The second major finding of our study is that regression analysis showed that, taking into
consideration the measured immune biomarkers, IL-10 is the best predictor of FM diagnosis, while
NN analysis showed that the three cytokines measured herein are the best predictors of the WPI
score and IL-10 the best immune biomarker predicting the SSS score. Comparable results indicating
lowered levels of anti-inflammatory cytokines were reported in a study that examined IL-4 and IL-10
gene expression patterns and serum concentrations in chronic widespread pain patients including
FM [48]. IL-4 is a T helper-2 (Th-2) cytokine, and IL-10 is a T regulatory (Treg) cytokine, and both may
suppress an immune response [9]. Thus, these authors found lower levels of the anti-inflammatory
cytokines IL-4 and IL-10 in patients with chronic pain, whereas there were no significant differences
in pro-inflammatory cytokines-chemokines including IL-2, CXCL-8, tumor necrosis factor (TNF)-α,
and transforming growth factor (TGF)-β1, another immune-regulatory cytokine. The authors concluded
that chronic pain is associated with lowered levels of anti-inflammatory and analgesic Th-2 (and Treg)
cytokine activity [48]. Both Th-2 and Treg cytokines attenuate the production of pro-inflammatory
M1 macrophage and Th-1 cytokines, suggesting that lower levels of IL-10 in FM may attenuate the
negative feedback on the inflammatory response system. Nevertheless, in our study some other
immune markers were suppressed (IL-6 and CXCL-8) or unchanged (hs-CRP), while in the study
of Üçeyler et al. [48] reduced Th-2 and Treg activities were not accompanied by signs of immune
activation in patients with chronic pain.
The above findings show that there should be another explanatory hypothesis, which combines
the effects of lowered IL-10 and IL-6 in explaining FM symptoms. One hypothesis is that this immune
profile may indicate loss of neuroprotection because IL-10 [49] and classical IL-6 signaling [45,50] have
(neuro)protective properties. For example, the lack of IL-10 may accelerate lesion expansion following
excitotoxic injuries in association with the onset of pain behaviors, while IL-10 may protect against
this type of lesions and the accompanying pain [51]. Furthermore, FM is accompanied by highly
increased serum levels of sgp130, the natural inhibitor of IL-6 trans-signaling and an inhibitor of the
activity of leukemia inhibitor factor (LIF) and oncostatin [52]. LIF is a growth factor that plays a role in
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genomic plasticity; it has regenerative effects and promotes T regulatory functions, and repair and
tolerance in the central nervous system [53,54]. Oncostatin is produced by myofibers and maintains the
regenerative capacity of stem cells in the muscle [55]. As such, it appears that FM may be accompanied
by disorders in the IL-6–sgp130 system and in regenerative IL-6-related cytokines.
Last but not least, our neural networks analysis showed that widespread pain symptoms
(WPI subscale score) are strongly predicted by sleep quality, perceived stress and anxiety, and that
the FM diagnosis is significantly predicted by sleep quality, perceived stress, anxiety, and aerobic
activities indicating that FM is much more than a pain condition. These results extend the findings of
Wolfe et al. [56] who reported that the original FM criteria (1990) [57] underestimated the prevalence of
FM by approximately 25% and that therefore it is more appropriate to use the revised ACR diagnostic
criteria, which comprise sleep problems, depression, fatigue, gastro-intestinal, and cognitive symptoms.
Our findings should be interpreted with regard to its limitations. Firstly, this study recruited
only females who represent the majority, but not all patients with FM. According to the last ACR
criteria, there are around 33% males in the FM population. Secondly, the sample size was rather small
particularly the normal control group. Therefore, our findings deserve replication in males using a
larger study sample. Thirdly, future research should include of a more comprehensive list of cytokines,
including M1 macrophage, Th-1, Th-2 and Th-17 cytokines altogether with other proteins implicated
in the immune status, such as sgp130, LIF, and oncostatin.
4. Materials and Methods
4.1. Participants
The present study had a cross-sectional case-control design embedded within a full randomized
controlled trial (N = 225) [58]. Sixty-seven female patients with FM were recruited at Sant Joan de Déu
Hospital (St. Boi de Llobregat, Spain) and 35 healthy female age-matched controls were contacted from
the hospital staff and acquaintances. The present work was performed in accordance with the ethical
standards laid down in the 1964 Declaration of Helsinki and its subsequent updates. The Fundació
Sant Joan de Déu (FSJD) Research Committee Board evaluated and approved the study protocol
(PIC-102–15, 12 November 2015).
The inclusion criteria for FM patients were: women, aged 18 to 65 years, FM diagnosis according
to American College of Rheumatology (ACR) 1990 criteria [57], understanding of Spanish, and give
written informed consent. The inclusion criteria for controls were: women, age-matched with FM
patients, absence of current or past FM diagnosis confirmed with the Fibromyalgia Symptoms Scale
(FS) [56], understanding of Spanish, and give written informed consent. Exclusion criteria for both
patients and controls were: recent injury/trauma, (auto-)immune and neuro-inflammatory diseases,
major psychiatric disorders (e.g., schizophrenia, psycho-organic syndromes), common cold or flu
during the day of blood extraction, needles’ phobia, BMI≥36 kg/m2 or weight≥110 kg, ≥8 caffeine/units
per day, smoker of ≥5 cigarettes per day, pregnancy or breastfeeding, use of local or oral corticosteroids,
use of immune modulatory drugs, and use of oral contraceptives.
4.2. Clinical Measurements
Clinical evaluation and sociodemographic characteristics were assessed by a health psychologist.
A comprehensive battery of self-reported scales was administered [58]. The Spanish version of the
Revised Fibromyalgia Impact Questionnaire (FIQ-R) [59,60] was administered to the FM patients in
order to assess FM severity. This scale includes 21 items on an 11-point numeric rating scale from 0
to 10. Time frame is the previous 7 days and the items are distributed into three associated domains:
physical function, overall impact, and severity of symptoms. Total scores can range from 0 to 100, with
higher scores indicating more functional impairment.
The Fibromyalgia Symptoms Score (FS) [56,61] is a 6-item self-report questionnaire that registers
the key symptoms of FM according to the latest revision of the ACR criteria. It includes assessment
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through the Widespread Pain Index (WPI), with a total score ranging from 0 to 19, and the Symptom
Severity Scale (SSS), which ranges from 0 to 12. It includes fatigue, trouble thinking/remembering,
and waking up tired or unrefreshed, pain or cramps in the lower abdomen, depression, and headache.
A total FS score of “fibromyalgia-ness” can be computed by summing WPI items and the SS scale
(ranging from 0–31).
The Hospital Anxiety and Depression Scale (HADS) [62–64] includes a total of 14 items divided in
two sub-scales of 7 items each, assessing anxiety (HADS-A) and depression (HADS-D) symptoms.
Scores range from 0 to 21 for both sub-scales. The general distress total score ranges from 0 to 42,
with higher scores indicating greater severity.
The Perceived Stress Scale (PSS-10) [65] is a 10 item scale that measures self-reported stress
level in the past month, with scores ranging from 0 to 40 being higher scores indicative of greater
perceived stress.
Using a semi-structured interview and visual analogue scales we also assessed health-related
variables including sleep quality (rated as 0 “poor quality of sleep” to 10 “high quality of sleep”), healthy
diet (rated 0 “very unhealthy diet” to 10 “very healthy diet”), menopause (yes/no), use of recreational
drugs (yes/no), smoking (yes/no), practice of aerobic exercise (yes/no), and use of antiinflammatories,
analgesics, antieplieptics, opioids, anxiolitics, and oral contraceptives [12]. Additionally, we computed
a comorbidity index based on number of present chronic comorbid conditions including cardiovascular,
endocrine, metabolic, neurodegenerative, rheumatological and respiratory comorbidities. Body mass
index (BMI) was calculated as body weight [kg]/height [m2].
4.3. Blood Assays
Blood samples were collected between 8.00–10.00 am. After blood extraction, samples were
centrifuged, and serum was separated and frozen at −80 ◦C until thawed for biomarkers assays, which
were performed in one and the same run. We used the Milliplex® Multiplex Assay (MerckMillipore®
Burlington, MA, USA) in a Luminex® platform to measure IL-6 (normal range 1–2 pg/mL; detection
limit: 0.11 pg/mL), CXCL-8 (normal range 1–157 pg/mL; detection limit: 0.12 pg/mL) and IL-10 (normal
range 4–17 pg/mL; detection limit: 0.51 pg/mL) (Human High Sensitivity T Cell Panel, catalog n
HSTCMAG-28SPMX adapted to the three mentioned cytokines). Hs-CRP (detection limit ≤1 mg/L) was
analyzed by turbidimetry in an Olympus AU5400 Autoanalyser (Olympus Iberia S.A.U., l’Hospitalet
de Llobregat, Spain).
4.4. Statistics
We used mean ± standard deviations (SDs) to represent continuous variables and percentages
for categorical variables. Biomarker data were first Ln transformed (IL-6, CXCL-8 and hs-CRP)
and consequently z transformed. For between-group comparisons, we computed one-way analyses
of variance for continuous values and χ2 tests for categorical values. Pearson’s product moment
correlation or Spearman’s rank order correlation coefficients were used to compute associations between
scale variables. Multivariate general linear model (GLM) analysis was used to assess the effects of
diagnosis on immune markers, while controlling for confounders including age, smoking, and BMI
groups, namely subjects with BMI <25.0 kg/m2, between 25–30 kg/m2 and >30 kg/m2. Consequently,
tests for between-subject effects were carried out to assess the effects of diagnosis on each of the
immune markers. We computed model-generated estimated marginal mean values and displayed
differences in mean z (±SE) values among diagnostic categories. A composite score integrating the
cytokines/chemokines was computed summing the values of z IL6 + z IL10 + z CXCL-8 [44]. All results
of multiple tests were p-corrected for false discovery rate (FDR) [64]. In addition, we employed
stepwise binary logistic regression analysis to assess the significant explanatory variables predicting
FM diagnosis (yes/no) as dependent variable and controls as reference group, and we computed Odds
ratios with 95% confidence intervals (CI), while Nagelkerke values were used as effects size estimates.
All analyses were bootstrapped (n = 1000), and these results are reported when differences between
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this approach and the non-bootstrapped results were observed. All the tests were two-tailed and a
p-value of 0.05 was used for statistical significance.
Multilayer perceptron neural network (NN) analyses were used to examine the more complex
associations between the FM diagnosis, WPI, and SSS scores (output variables), and immune markers,
age, BMI, smoking, and clinical rating scales as input variables in automated feedforward architecture
models. The networks were trained using one or two hidden layers with a variable number of
nodes (up to 7) with batch (gradient descent) and minibatch (automatically determined number
of records). As stopping rule, we used one consecutive step with no further decrease in the error
term. The maximum number of training epochs was set at 200, while the network weights were
randomly initialized. Part of the cases (46.6%) were assigned to the training set (to estimate the network
parameters), 20.0% to the testing set (to prevent overtraining) and 33.3% to the holdout set (to evaluate
the final network). We computed error, relative error and importance of each of the input variables in
sensitivity analyses. The importance (or relative importance) reflects the strength of the relationship
between the input variables and their multiple interactions and the output variable, and as such
indicates the predictor importance. These predictor importance values are relative because they are
computed yielding a sum of 1 or 100%. These relative values are computed based on the weights
that describe the input variables as well as their multiple interactions in the neural network (SPSS,
2019 [65]). All statistical analyses were performed using IBM SPSS windows version 25 (IBM, Armonk,
NY, USA).
5. Conclusions
In our FM patients, we found lowered levels of IL-6, IL-10, and CXCL-8, independently from
the effects of confounder variables, whereas hs-CRP was not altered in FM. IL-10 is the best immune
biomarker predicting FM diagnosis. The severity of widespread pain is best predicted by quality of
sleep, perceived stress, anxiety, and the three cytokines, while severity of FM is best predicted by stress,
anxiety, and IL-10.
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FM Fibromyalgia
BMI Body Mass Index
IL Interleukin
hs-CRP High Sensitivity C-Reactive Protein
WPI Widespread Pain Index
SSS Symptom Severity Scale
HADS Hospital Anxiety and Depression Scale
PSS-10 Perceived Stress Scale
IRS Immune-inflammatory response system
ADs Antidepressants
NN Neural Networks
ACR American College of Rheumatology
FS Fibromyalgia Symptoms Scale
FIQ-R Fibromyalgia Impact Questionnaire
SDs Standard deviations
GLM Multivariate general linear model
FDR False discovery rate
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ROC Receiving operating curve
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